Diagenode

>>>   Click for Diagenode’s approach to COVID-19

The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer


Daures M, Ngollo M, Judes G, Rifaï K, Kemeny JL, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D

Prostate cancer is themost common cancer in men. It has been clearly established that genetic and epigenetic alterations of histone 3 lysine 27 trimethylation (H3K27me3) are common events in prostate cancer. This mark is deregulated in prostate cancer (Ngollo et al., 2014). Furthermore, H3K27me3 levels are determined by the balance between activities of histone methyltransferase EZH2 (enhancer of zeste homolog 2) and histone demethylase JMJD3 (jumonji domain containing 3). It is well known that EZH2 is upregulated in prostate cancer (Varambally et al., 2002) but only one study has shown overexpression of JMJD3 at the protein level in prostate cancer (Xiang et al., 2007). 
Here, the analysis of JMJD3 and EZH2 were performed at mRNA and protein levels in prostate cancer cell lines (LNCaP and PC-3), normal cell line (PWR-1E), and as well as prostate biopsies.

Tags
Antibody

Share this article

Published
February, 2016

Source

Products used in this publication

  • ChIP-seq Grade
    C15410039-50
    EZH2 Antibody - ChIP-seq Grade
  • ChIP-seq Grade
    C15410069
    H3K27me3 Antibody - ChIP-seq Grade
  • Mouse IgG
    C15410206
    Rabbit IgG

Events

  • ChIP workshop
    Diagenode
    Sep 21-Sep 22, 2021
  • DNA methylation workshop: Master MeDIP assay
    Diagenode
    Sep 30, 2021
  • DNA methylation workshop: Become an expert at RRBS
    Diagenode
    Oct 1-Oct 31, 2021
 See all events

News

 See all news


The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.



  ABOUT SSL CERTIFICATES

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics